BRIEF-Cingulate Reports Safety Results From Final Phase 3 Trials For Lead ADHD Asset CTX-1301

Reuters03-04

March 4 (Reuters) - Cingulate Inc CING.O:

CINGULATE REPORTS SAFETY RESULTS FROM FINAL PHASE 3 TRIALS FOR LEAD ADHD ASSET CTX-1301: ON TRACK TO FILE FOR FDA APPROVAL MID-2025
CINGULATE INC - NO SERIOUS ADVERSE EVENTS REPORTED IN CTX-1301 STUDIES

Source text: ID:nGNX6DHw88

Further company coverage: CING.O

(Reuters.Briefs@thomsonreuters.com)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2516710026?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-03-04 22:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2516710026","market":"us","top_or_hot":-1,"title":"BRIEF-Cingulate Reports Safety Results From Final Phase 3 Trials For Lead ADHD Asset CTX-1301","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Cingulate Reports Safety Results From Final Phase 3 Trials For Lead ADHD Asset CTX-1301 </title></head><body><p><span>March 4 (Reuters)</span><span> - </span>Cingulate Inc <span>CING.O</span>:</p><ul><li><p>CINGULATE REPORTS SAFETY RESULTS FROM FINAL PHASE 3 TRIALS FOR LEAD ADHD ASSET CTX-1301: ON TRACK TO FILE FOR FDA APPROVAL MID-2025</p></li><li><p>CINGULATE INC - NO SERIOUS ADVERSE EVENTS REPORTED IN CTX-1301 STUDIES</p></li></ul><p>Source text: <span>ID:nGNX6DHw88</span></p><p>Further company coverage: <span>CING.O</span></p><p> (Reuters.Briefs@thomsonreuters.com)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Cingulate Reports Safety Results From Final Phase 3 Trials For Lead ADHD Asset CTX-1301</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Cingulate Reports Safety Results From Final Phase 3 Trials For Lead ADHD Asset CTX-1301\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-03-04 22:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Cingulate Reports Safety Results From Final Phase 3 Trials For Lead ADHD Asset CTX-1301 </title></head><body><p><span>March 4 (Reuters)</span><span> - </span>Cingulate Inc <span>CING.O</span>:</p><ul><li><p>CINGULATE REPORTS SAFETY RESULTS FROM FINAL PHASE 3 TRIALS FOR LEAD ADHD ASSET CTX-1301: ON TRACK TO FILE FOR FDA APPROVAL MID-2025</p></li><li><p>CINGULATE INC - NO SERIOUS ADVERSE EVENTS REPORTED IN CTX-1301 STUDIES</p></li></ul><p>Source text: <span>ID:nGNX6DHw88</span></p><p>Further company coverage: <span>CING.O</span></p><p> (Reuters.Briefs@thomsonreuters.com)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nTUA1BQKMZ:1","article_id":"2516710026","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2516710026","pubTimestamp":1741097119,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Cingulate Reports Safety Results From Final Phase 3 Trials For Lead ADHD Asset CTX-1301 March 4 (Reuters) - Cingulate Inc CING.O:CINGULATE REPORTS SAFETY RESULTS FROM FINAL PHASE 3 TRIALS FOR LE","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","CINGW":"CINGULATE INC C/WTS 03/12/2026 (TO PUR COM)","CING":"CINGULATE INC."},"translate_title":"BRIEF-Cingulate报告ADHD资产CTX-1301最终3期试验的安全性结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CING":0.9,"CINGW":0.9},"content_text":"BRIEF-Cingulate Reports Safety Results From Final Phase 3 Trials For Lead ADHD Asset CTX-1301 March 4 (Reuters) - Cingulate Inc CING.O:CINGULATE REPORTS SAFETY RESULTS FROM FINAL PHASE 3 TRIALS FOR LEAD ADHD ASSET CTX-1301: ON TRACK TO FILE FOR FDA APPROVAL MID-2025CINGULATE INC - NO SERIOUS ADVERSE EVENTS REPORTED IN CTX-1301 STUDIESSource text: ID:nGNX6DHw88Further company coverage: CING.O (Reuters.Briefs@thomsonreuters.com)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2516710026"}